IL6 and type 2 diabetes mellitus: The presence of subclinical systemic inflammation in obese diabetic patients, increased levels of C–reactive protein, interleukine‐6 (IL‐6), and tumor necrosis factor‐α, predicts the development of T2DM with reduced insulin sensitivity in peripheral tissues.32